Emicizumab treatment in chronic intermittent haemodialysis.

Weise, Maria; Siegemund, Annelie; Böhme, Lydia; Grey, Daniel; Halbritter, Jan; Petros, Sirak; Pfrepper, Christian

Weise, Maria; Siegemund, Annelie; Böhme, Lydia; Grey, Daniel; Halbritter, Jan; Petros, Sirak; Pfrepper, Christian.

Afiliação

Weise M; Division of Haemostaseology, Department of Haematology, Cellular Therapy and Haemostaseology, University of Leipzig Medical Centre, Leipzig, Germany.
Siegemund A; Division of Haemostaseology, Department of Haematology, Cellular Therapy and Haemostaseology, University of Leipzig Medical Centre, Leipzig, Germany.
Böhme L; Division of Haemostaseology, Department of Haematology, Cellular Therapy and Haemostaseology, University of Leipzig Medical Centre, Leipzig, Germany.
Grey D; Dialysis Centre Leipzig "Thomasium", Leipzig, Germany.
Halbritter J; Division of Nephrology, Department of Internal Medicine, University of Leipzig Medical Centre, Leipzig, Germany.
Petros S; Division of Haemostaseology, Department of Haematology, Cellular Therapy and Haemostaseology, University of Leipzig Medical Centre, Leipzig, Germany.
Pfrepper C; Medical ICU, University of Leipzig Medical Centre, Leipzig, Germany.

Haemophilia ; 28(1): e20-e22, 2022 Jan.

Article em En | MEDLINE | ID: mdl-34687109

Assuntos

Anticorpos Biespecíficos; Hemofilia A; Anticorpos Monoclonais Humanizados/uso terapêutico; Fator VIII; Humanos; Diálise Renal/efeitos adversos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Hemofilia A Limite: Humans Idioma: En Revista: Haemophilia Assunto da revista: HEMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google